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Abstract
Objective—We evaluated the utility of the World Health Organization Fracture Risk Assessment 
Tool (FRAX) in assessing fracture risk in patients with human immunodeficiency virus (HIV) and 
vitamin D deficiency.
Methods—This was a retrospective study of HIV-infected patients with co-existing vitamin D 
deficiency at the Atlanta Veterans Affairs Medical Center. Bone mineral density (BMD) was 
assessed by dual-energy X-ray absorptiometry (DEXA), and the 10-year fracture risk was 
calculated by the WHO FRAX algorithm. Two independent radiologists reviewed lateral chest 
radiographs for the presence of subclinical vertebral fractures.
Results—We identified 232 patients with HIV and vitamin D deficiency. Overall, 15.5% of 
patients met diagnostic criteria for osteoporosis on DEXA, and 58% had low BMD (T-score 
between −1 and −2.5). The median risk of any major osteoporotic and hip fracture by FRAX score 
was 1.45 and 0.10%, respectively. Subclinical vertebral fractures were detected in 46.6% of 
patients. Compared to those without fractures, those with fractures had similar prevalence of 
osteoporosis (15.3% versus 15.7%; P>.999), low BMD (53.2% versus 59.3%; P = .419), and 
similar FRAX hip scores (0.10% versus 0.10%; P = .412). While the FRAX major score was lower 
in the nonfracture group versus fracture group (1.30% versus 1.60%; P = .025), this was not 
clinically significant.
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Conclusion—We found a high prevalence of subclinical vertebral fractures among vitamin D–
deficient HIV patients; however, DEXA and FRAX failed to predict those with fractures. Our 
results suggest that traditional screening tools for fragility fractures may not be applicable to this 
high-risk patient population.
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INTRODUCTION
It has been well established that individuals infected with the human immunodeficiency 
virus (HIV) are more prone to decreased bone mineral density (BMD) and osteoporosis (1–
4). Furthermore, a growing amount of data have demonstrated a high prevalence of vitamin 
D deficiency among HIV-infected individuals (5–10), which has also been associated with 
increased risk of developing decreased BMD (11,12). The pathophysiologic mechanisms of 
bone disease in HIV infection are complex and not fully understood. In addition to 
traditional risk factors, individuals with HIV are at increased risk for decreased BMD due to 
concomitant risk factors such as malnutrition, vitamin D deficiency, hypogonadism, 
antiretroviral therapies, chronic inflammation, and HIV infection itself (5,13–17).
Currently, the optimal screening for bone disease in HIV disease remains controversial, and 
it is unclear whether the World Health Organization (WHO) Fracture Risk Assessment Tool 
(FRAX) algorithm applies to this patient population. The WHO FRAX algorithm, used to 
calculate the 10-year probability of a hip fracture or major osteoporotic fracture, has not 
been fully validated in HIV-infected individuals. Similarly, fracture risk assessment by T-
scores on dual-energy X-ray absorptiometry (DEXA) alone may be inadequate to reliably 
screen for patients with HIV who are at a higher risk for fracture than their HIV-negative 
counterparts. As seen in other causes of secondary osteoporosis, measurements of BMD 
alone may be inadequate to predict fracture risk in HIV-infected individuals (18,19).
These data raise the question of whether traditional screening tools are sufficient to identify 
those at risk for bone disease in this high-risk population of patients with concomitant HIV 
and vitamin D deficiency, which has important clinical implications from both a preventive 
and treatment perspective. Thus, the aim of our study was to investigate the utility of the 
FRAX risk assessment tool and WHO criteria for osteoporosis based on T-scores in the 
vitamin D–deficient HIV population. The prevalence of subclinical vertebral fractures in this 
patient population was also investigated.
METHODS
Study Design and Participants
We performed a retrospective study of 232 patients with HIV and co-existing vitamin D 
deficiency as part of a substudy investigating the prevalence of vitamin D deficiency in the 
HIV patient population at the Atlanta Veterans Affairs (VA) Medical Center (20). Data were 
obtained from the HIV Atlanta VA cohort, a clinical database collecting longitudinal data 
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from electronic medical records on all HIV-infected patients seen at the Atlanta VA Medical 
Center since 1982. All patients with HIV and a 25-hydroxyvitamin D (25[OH]D) level <20 
ng/mL collected during routine medical care between 2007 and 2010 were identified. 
Routine care included obtaining a DEXA scan on patients with vitamin D deficiency. DEXA 
testing was not done routinely for subjects without vitamin D deficiency. Patients were then 
included in our study only if they had BMD assessment by DEXA, calculated FRAX scores, 
and lateral chest radiographs during the study period. The chest radiographs had been 
obtained during routine clinical care for a variety of indications. Individuals who had 
received bisphosphonate therapy prior to or during the study period were excluded. Patient 
characteristics (age, sex, and race), body composition (height, weight, and body mass index 
[BMI]), medical comorbidities (diabetes mellitus, hypertension, tobacco use, alcohol use, 
and hepatitis B and/or C co-infection), type of antiretroviral therapy, and other potential risk 
factors for low BMD were obtained from electronic medical records. Standard, routine 
laboratory assays were used to measure baseline biomarkers of bone metabolism, including 
calcium, parathyroid hormone (PTH), alkaline phosphatase, and phosphorous, as well as 
HIV-related parameters (CD4 lymphocyte count and HIV RNA viral load). The liquid 
chromatography/tandem mass spectrometry method was used for measuring 25(OH)D levels 
(Quest Laboratories). Vitamin D deficiency was defined as a 25(OH)D level <20 ng/mL. The 
glomerular filtration rate was estimated by the Cockcroft-Gault equation. The study was 
approved by the Emory University Institutional Review Board and the VA Research and 
Development Committee.
Assessment of BMD and Fractures
BMD was assessed by DEXA (Hologic, Inc.). Criteria established by the WHO were used to 
diagnose those with osteoporosis (hip or spine T score ≤ −2.5) or low bone density (hip or 
spine T score > −2.5 and < −1.0). Patients classified as having osteoporosis or low bone 
density were compared with those patients with normal BMD (hip and spine T score > 
−1.0). The 10-year probabilities of hip fracture and of a major osteoporotic fracture were 
calculated using the WHO FRAX algorithm, which integrates several clinical risk factors 
(age, sex, weight, height, previous fracture history, parent hip fracture, smoking history, use 
of glucocorticoids, rheumatoid arthritis, secondary osteoporosis, and alcohol consumption 
≥3 units/day) with BMD (T score) at the femoral neck. FRAX prediction values were 
calculated based on a patient’s risk at the time of the DEXA examination. The presence of 
subclinical vertebral fractures was assessed by lateral chest radiographs, which were 
interpreted by two independent radiologists who were blinded to each other’s read. Using 
the Genant et al (21) semiquantitative method, thoracic and lumbar vertebrae were graded on 
visual inspection of lateral spinal images as grade 0 (normal), grade 1 fracture (mildly 
deformed; 20 to 25% reduction in height), grade 2 fracture (moderately deformed; 26 to 
40% reduction in height), and grade 3 (severely deformed; approximately 40% or greater 
reduction in height). There was 90% agreement between the two readers, and disagreements 
were resolved by consensus.
Statistical Analysis
Results for continuous variables with a nonnormal distribution are summarized as median 
values with interquartile intervals or as proportions for categorical variables. The Mann-
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Whitney U test was used to compare the difference in nonnormally distributed variables. The 
chi-square test was used for comparison of categorical variables. Multivariate logistic 
regression models, with the presence of subclinical vertebral fracture as a binary dependent 
variable, were used to adjust for potential confounding factors. Variables examined included 
age, sex, race, BMI, type of antiretroviral therapy, CD4 T-cell count, HIV RNA viral load, 
hypertension, hepatitis B co-infection, hepatitis C co-infection, alcohol use, tobacco use, 
osteoporosis or osteopenia status, FRAX scores, renal function, serum 25(OH)D calcium 
and phosphorus concentrations, and plasma PTH concentrations. Analyses were performed 
with SPSS software (version 21.0, SPSS, Inc, Chicago, IL). Statistical significance was 
based on 2-tailed tests, and P values ≤.05 were considered significant.
RESULTS
Patient Characteristics
We identified 232 patients with HIV (median CD4 count, 494.5 cells/mm3; interquartile 
range [IQR], 306.5 to 673.8) and vitamin D deficiency (median 25[OH]D, 13 ng/mL; IQR, 
9.0 to 16.0). The majority of patients were male (97.8%), African American (90.1%), and 
with a median age of 49.1 years (IQR, 42.8 to 56.1). Most patients were receiving 
antiretroviral therapy (81.5%), and almost two-thirds had an undetectable HIV viral load 
(61%). The study patient characteristics are further shown in Table 1.
Baseline BMD and Prevalence of Subclinical Vertebral Fractures
Overall, 73.5% of our patients with HIV and co-existing vitamin D deficiency had low 
BMD. The prevalence of patients meeting diagnostic criteria for osteoporosis by DEXA was 
15.5% (n = 36), and 58% (n = 130) had low bone density (T score between −2.5 and −1 at 
the hip or spine). Notably, there was a high prevalence of subclinical vertebral fractures 
detected on lateral chest radiographs (46.6%), and the majority of these fractures were grade 
1 (90.7%).
Characteristics of Patients According to Presence or Absence of Subclinical Vertebral 
Fractures
When compared to the group of patients with subclinical vertebral fractures, those without 
fractures had similar prevalence of osteoporosis (15.3% versus 15.7%; P>.999) and low 
bone density (53.2% versus 59.3%; P = .419) by WHO criteria on DEXA (Fig. 1). Other 
than being slightly older (52.1 versus 48.2 years; P = .001), patients with subclinical 
vertebral fractures had no statistically significant differences in patient demographics, 
antiretroviral regimen, or medical comorbidities compared to those without fractures. 
Phosphorous was the only marker of bone metabolism that was statistically different 
between the two groups (3.1 versus 3.3 mg/dL; P = .006), but the difference was not 
clinically significant. Density at the hip was statistically higher in the nonfracture group 
versus fracture group (1.011 versus 0.965 g/cm2; P = .023), but there was no difference in 
density at the spine between the two groups. Femoral neck T score was also statistically 
higher in the nonfracture group versus fracture group (−1.00 versus −1.40; P = .028), but 
there was no difference in T score at the spine. Characteristics of our study patients 
according to the presence or absence of subclinical vertebral fractures are shown in Table 2.
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Ten-Year Estimate of Fracture Risk
The median risk of any major osteoporotic and hip fracture calculated by the WHO FRAX 
algorithm for the entire study population was 1.45% (IQR, 1.00 to 2.70) and 0.10% (IQR, 
0.00 to 0.40), respectively, well below the recommended threshold to initiate pharmacologic 
therapy. Compared to those without fractures, those with subclinical vertebral fractures had 
similar FRAX hip (0.10% versus 0.10%; P = .412) scores. The FRAX risk score for any 
major osteoporotic fracture was statistically higher in the fracture group (1.60% versus 
1.30%; P = .025) but was not clinically relevant, as both scores were well below the 
recommended threshold for pharmacologic treatment. Furthermore, when the FRAX scores 
were adjusted for the presence of vertebral fractures on lateral chest radiographs in our 
patients, there was no significant difference between the baseline FRAX and modified 
scores.
Risk Factors for Future Fracture Risk
After multivariable analysis, only older age and diabetes were associated with future risk of 
subclinical vertebral fractures. Other variables that were not predictive of vertebral fractures 
included sex, race, BMI, CD4 count, HIV viral load, type of antiretroviral therapy, 
hypertension, hepatitis B co-infection, hepatitis C co-infection, alcohol use, tobacco use, 
osteoporosis and osteopenia status, FRAX scores, renal function, serum 25(OH)D and 
calcium concentrations, and plasma PTH concentrations.
DISCUSSION
Our study found a high prevalence of subclinical vertebral fractures among HIV patients 
with vitamin D deficiency, but screening with DEXA and the WHO FRAX algorithm failed 
to distinguish between patients with and without subclinical vertebral fractures. 
Osteoporosis and decreased BMD (T score < −1.0) was found in 73.5% of our study 
patients, similar to prior data reported among HIV patients in the literature (3,22). However, 
subclinical vertebral fractures were detected in about half of our study participants (46.6%), 
which is almost twice as prevalent as had been reported in recent studies (23–25). Most 
notably, we found a similar prevalence of osteoporosis and decreased BMD between patients 
with and without subclinical vertebral fractures. Finally, there was no clinically significant 
difference in the calculated WHO FRAX score between patients with and without 
subclinical vertebral fractures, consistent with prior studies that suggest poor sensitivity of 
FRAX in HIV patients (26,27).
It is well established that individuals infected with HIV are at an increased risk for decreased 
BMD and osteoporosis. Brown et al (3) reported a 67% prevalence of low BMD and 15% 
prevalence of osteoporosis in a meta-analysis among HIV-infected individuals, a 3.7-fold 
increase compared to age-matched non–HIV infected persons. Mounting data have now also 
shown that fracture prevalence is significantly higher among the HIV patient population, 
with reported overall fracture rates 24 to 70% higher than the general population (1,28–31). 
In particular, HIV-infected patients have been shown to have high rates of vertebral fractures 
and may have more severe and multiple fractures compared to age-matched non–HIV 
infected controls (24,25). This is of clinical concern, as radiographic vertebral fractures are 
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associated with higher risk for hip and other future fractures (32), and age-related increases 
in fracture rates appear to be greater in HIV-infected individuals compared to controls, 
suggesting that fracture rates may further increase as the HIV-infected patient population 
ages (1).
The pathogenesis of HIV-associated bone loss is complex and likely multifactorial. In 
addition to traditional risk factors (advanced age, gender, low bone mass index, smoking, 
alcohol use, vitamin D deficiency), patients with HIV are at increased risk for decreased 
BMD and osteoporosis due to chronic malnutrition, weight loss, and hypogonadism. 
Furthermore, several studies have implicated HIV infection itself in increased risk for 
decreased BMD causing alterations in bone remodeling (33,34). In vitro, HIV viral proteins 
have been shown to increase levels of RANK ligand, promoting osteoclastogenesis (35), and 
also are associated with suppression of osteoblast activity and increased osteoblast apoptosis 
(33,35). In addition, chronic inflammation and T-cell activation resulting in increased 
production of pro-inflammatory cytokines may further promote osteoclast activation and 
high bone turnover in HIV disease (35,36). Finally, treatment with antiretroviral therapy has 
also been associated with increased bone loss, in particular protease inhibitors and tenofovir 
(16,37).
In agreement with other studies, we found that the WHO FRAX algorithm is a poor 
screening tool to assess fracture risk in the HIV patient population. The study of Calmy et al 
(27) was the first to demonstrate that FRAX has a poor sensitivity in HIV patients and fails 
to distinguish between HIV patients with normal BMD and those with decreased BMD. A 
subsequent study by Gazzola et al (26) found that when compared to DEXA screening, 
FRAX scores failed to identify a large number of HIV patients with decreased BMD, with a 
sensitivity of only 22%. Furthermore, when the authors added HIV as a secondary cause of 
osteoporosis to calculate a modified FRAX score, the sensitivity only increased to 37.5%, 
still grossly underestimating those at risk for bone disease (26).
Recently, Porcelli et al (23) found a high prevalence of radiologic vertebral fractures in HIV 
patients (27%), yet over half of these patients with fractures had normal or only mildly 
reduced BMD on DEXA assessment. Our study differs from that of Porcelli et al in that we 
found a significantly higher prevalence of subclinical vertebral fractures in our HIV patient 
population, likely due to co-existing vitamin D deficiency, which further increased fracture 
risk. Furthermore, subclinical vertebral fractures in our study were not associated with lower 
BMD on DEXA.
Current guidelines recommend DEXA screening in all HIV patients who are 
postmenopausal, have a fracture history, or are 50 years of age or older with an additional 
traditional risk factor for low BMD (38). Based on the results of our study, current screening 
guidelines may underdiagnose many of these high-risk individuals. Thus, we propose 
considering the use of lateral spine imaging to screen for subclinical vertebral fractures in 
HIV patients, especially given that this is a low-cost and widely available screening 
modality. The presence of a subclinical vertebral fracture may provide grounds for initiating 
pharmacologic therapy for osteoporosis in patients who would have not otherwise qualified 
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based on a normal or only slightly decreased BMD on DEXA and/or calculated FRAX 
scores below the current recommended threshold to treat.
Our study has several limitations. Our study patient population lacked heterogeneity (mostly 
African American males); thus, our findings may not be applicable to other ethnic groups 
and/or females. All patients were vitamin D deficient, which may have increased the risk for 
subclinical vertebral fractures compared to HIV individuals who are vitamin D sufficient. 
Furthermore, we did not have further detailed information regarding the vitamin D status of 
our patients and whether they had received vitamin D replacement therapy prior to or during 
the study period. It is also unknown whether treatment with vitamin D replacement or other 
pharmacologic therapy would have changed the study outcomes (prevalence of fracture and 
decreased BMD). Our study also lacked data regarding risk factors for fractures, such as 
glucocorticoid or testosterone use, testosterone levels, nutritional status, prior fracture 
history or trauma, or HIV defining illnesses. Notably, our patient population represents a 
relatively well-controlled cohort, with a median CD4 count of 494.5, most of whom are on 
treatment (81.5%) and with undetectable viral load (61%). We may have underestimated 
fracture risk by using lateral chest radiographs as the only imaging modality to detect 
subclinical vertebral fractures. The fracture rate may actually have been higher if dedicated 
lateral spine radiographs had been used. Finally, we do not have fracture data on HIV 
patients without vitamin D deficiency and cannot comment on the prevalence of vertebral 
fractures in this population. Notably, the FRAX score has not been validated in younger 
patients, who constituted the majority of our patient population. Whether this contributes to 
the lack of discrimination of FRAX with respect to fracture risk in our study is uncertain. 
However, HIV patients tend to be a younger population at risk for fractures in general, and 
this may further highlight the lack of applicability of FRAX in this population. Finally, the 
chest X-rays were performed at the clinical discretion of the treating physician. Whether the 
indication for these chest X-rays affect the baseline fracture risk for these patients is 
unknown.
CONCLUSION
In conclusion, our study demonstrated a high prevalence of subclinical vertebral fractures in 
HIV patients with co-existing vitamin D deficiency. Screening with DEXA and the WHO 
FRAX algorithm grossly underestimated fracture risk in this patient population and failed to 
discriminate between patients with and without subclinical vertebral fractures. Additional 
imaging and/or a lower threshold to initiate pharmacologic therapy may be warranted in this 
high-risk group.
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Fig. 1. 
Bone mineral density in patients with HIV and vitamin D deficiency with and without 
subclinical vertebral fractures on lateral chest radiographs. Compared to the group of 
patients with subclinical vertebral fractures, those without fractures has similar prevalence of 
osteoporosis and low bone density by WHO criteria on DEXA.
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Table 1
Baseline Characteristics of Study Patients and According to the Presence or Absence of Subclinical Vertebral 
Fracture on Lateral Chest Radiograph
Patient characteristics
Total population
(N = 232)
Fracture present
(n = 108)
Fracture absent
(n = 124) P value
Male (%) 227 (97.8) 108 (100.0) 119 (96.0) .666
Age (years) (IQR) 49.1 (42.8–56.2) 52.1 (46.3–58.5) 48.2 (41.0–54.1) .001
Body mass index (kg/m2) (IQR) 25.9 (23.1–30.1) 26.2 (22.9–30.3) 25.8 (23.2–29.9) .763
Medical Comorbidities
Diabetes mellitus (%) 29 (12.5) 9 (8.3) 21 (16.1) .078
Hypertension (%) 129 (55.6) 67 (62.0) 62 (50.0) .085
Cardiovascular disease (%) 27 (11.6) 13 (12.0) 14 (11.3) >.999
Current or prior tobacco abuse (%) 113 (48.7) 51 (47.2) 62 (50.0) .695
Current or prior alcohol abuse (%) 45 (19.4) 22 (20.4) 23 (18.5) .742
Chronic hepatitis B co-infection (%) 24 (10.3) 12 (11.1) 12 (9.7) .610
Chronic hepatitis C co-infection (%) 33 (14.2) 16 (14.8) 17 (13.7) .852
Antiretroviral Therapy
PI-containing regimen (%) 78 (33.6) 31 (28.7) 47 (37.9) .164
EFV-containing regimen (%) 88 (37.9) 44 (40.7) 44 (35.5) .419
TDF-containing regimen (%) 133 (57.3) 62 (57.4) 71 (57.3) >.999
Atripla (%) 70 (30.2) 35 (32.4) 35 (28.2) .567
No therapy (%) 43 (18.5) 16 (14.8) 27 (21.8) .181
Biological Data
CD4 cell count (cells/mm2) (IQR) 494.5 (306.5–673.8) 480.0 (300.3–657.3) 506.0 (327.0–710.0) .416
Undetectable HIV RNA level (%) 141 (61.0) 69 (63.9) 72 (58.1) .345
25-hydroxyvitamin D (ng/mL) (IQR) 13.0 (9.0–16.0) 14.0 (10.0–16.0) 13.0 (9.0–16.0) .425
Calcium (mg/dL) (IQR) 9.3 (9.0–9.5) 9.2 (8.9–9.5) 9.3 (9.0–9.5) .351
Phosphorous (mg/dL) (IQR) 3.2 (2.9–3.6) 3.1 (2.7–3.6) 3.3 (3.0–3.7) .006
Parathyroid hormone (pg/mL) (IQR) 56.4 (39.1–80.6) 51.1 (36.4–78.9) 62.1 (41.7–83.1) .093
Alkaline phosphatase (units/L) (IQR) 78.0 (60.3–94.0) 78.0 (65.0–96.3) 78.0 (60.0–94.0) .604
eGFR (mL/min/1.73 mm2) (IQR) 93.6 (80.5–111.6) 92.9 (77.4–110.0) 94.2 (81.7–113.0) .326
Bone Mineral Density Data
Osteopenia according to T score (%) 130 (58.0) 64 (59.3) 66 (53.2) .419
Osteoporosis according to T score (%) 36 (15.5) 17 (15.7) 19 (15.3) 1
Spine T score (IQR) −1.00 (−1.90 to −0.10) −0.85 (−1.88 to −0.03) −1.00 (−1.98 to −0.10) .341
Femoral neck T score (IQR) −1.10 (−1.80 to −0.40) −1.40 (−1.90 to −0.60) −1.00 (−1.60 to −0.40) .028
Hip T score (IQR) −0.90 (−1.50 to −0.40) −1.05 (−1.63 to −0.45) −0.80 (−1.40 to −0.30) .116
Spine Z score (IQR) −0.30 (−0.80–0.15) −0.50 (−1.30–0.375) −0.75 (−1.70–0.20) .376
Hip Z score (IQR) −0.30 (−0.80–0.15) −0.40 (−1.0–0.03) −0.30 (−0.80–0.20) .562
Density at spine (g/cm2) (IQR) 1.071 (0.974–1.180) 1.071 (0.973–1.180) 1.071 (0.976–1.174) .911
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Patient characteristics
Total population
(N = 232)
Fracture present
(n = 108)
Fracture absent
(n = 124) P value
Density at hip (g/cm2) (IQR) 0.985 (0.891–1.088) 0.965 (0.862–1.080) 1.011 (0.923–1.092) .023
FRAX score, 10-year risk of a major osteoporotic 
fracture (IQR) 1.45 (1.00–2.70) 1.60 (1.1–3.08) 1.30 (0.90–2.50) .025
FRAX score, 10-year risk of a hip fracture (IQR) 0.10 (0.00–0.40) 0.10 (0.00–0.50) 0.10 (0.00–0.30) .412
Abbreviations: EFV= efavirenz; eGFR= estimated glomerular filtration rate; FRAX = Fracture Risk Assessment Tool; HIV = human 
immunodeficiency virus; IQR = interquartile range; PI= protease inhibitor; TDF= tenofovir.
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